Which symptom should a client report during treatment with pertuzumab?

Which symptom should a client report during treatment with pertuzumab?

• A. Shortness of breath
• B. Mild headaches
• C. Occasional fatigue
• D. All of the above

Answer: (A)

When a client is receiving treatment with pertuzumab, it is crucial for them to report shortness of breath. This symptom is particularly important because pertuzumab, like other monoclonal antibodies used in cancer treatment, can lead to potential cardiovascular complications, including heart failure, which may manifest as shortness of breath. It is essential to differentiate between typical side effects and symptoms that may indicate a more serious condition. Shortness of breath can indicate an acute change in the client’s status and requires immediate assessment. While mild headaches and occasional fatigue are common side effects of many cancer therapies, they are usually less urgent and may not require immediate reporting. Thus, while all the listed symptoms can occur, shortness of breath represents a critical warning sign that prompts immediate medical attention, making it the most crucial symptom to report during treatment with pertuzumab.

When a client is receiving treatment with pertuzumab, it is crucial for them to report shortness of breath. This symptom is particularly important because pertuzumab, like other monoclonal antibodies used in cancer treatment, can lead to potential cardiovascular complications, including heart failure, which may manifest as shortness of breath. It is essential to differentiate between typical side effects and symptoms that may indicate a more serious condition. Shortness of breath can indicate an acute change in the client’s status and requires immediate assessment.

While mild headaches and occasional fatigue are common side effects of many cancer therapies, they are usually less urgent and may not require immediate reporting. Thus, while all the listed symptoms can occur, shortness of breath represents a critical warning sign that prompts immediate medical attention, making it the most crucial symptom to report during treatment with pertuzumab.